Stockhub

RareCan: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 August 2022

22 July 2022

5 July 2022

  • curprev 11:1711:17, 5 July 2022 >Crowdcube 3,722 bytes +100 No edit summary undo
  • curprev 10:4210:42, 5 July 2022 >Crowdcube 3,622 bytes +18 No edit summary undo
  • curprev 10:4010:40, 5 July 2022 >Crowdcube 3,604 bytes +3,604 Created page with "thumb|RareCan logo == Summary == RareCan is a direct-to-patient clinical trial platform, harnessing the power of patients and data aiming to reduce costs and increase the success rate of rare cancer trials for the $143bn global cancer drug market. Raising to grow the team and develop platform capabilities. * First commercial contract agreed * Over 800 members with rare cancer & 3 charity partnerships in place * NHS Ethics approved process for..."
Retrieved from "https://stockhub.co/research/RareCan"